EUVIMEDEUVIMED entdecken
Open Access

CD22 TCR-engineered T cells exert antileukemia cytotoxicity without causing inflammatory responses

Kilyna A Nguyen iD, Zhihui Liu iD, John S Davies iD, Crystal P McIntosh, Lindsey M Draper iD, Scott M Norberg iD, Zachary Rae, Sooraj R Achar iD, Gregoire Altan-Bonnet iD, Ling Zhang, Xiaolin Wu iD, Thomas J Meyer iD und 4 weitere

Science Advances · 2025

DOI: 10.1126/sciadv.adq4297 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Science Advances, 2025. Verfasst von Kilyna A Nguyen und 15 weiteren Autor:innen. Beteiligte Einrichtung: Center for Immuno-Oncology, Center for Cancer Research (CCR), National Cancer Institute (NCI), National Institutes of Health (NIH), Bethesda, MD, USA. Hauptthemen laut MEDLINE: Sialic Acid Binding Ig-like Lectin 2, Receptors, Chimeric Antigen, Inflammation, Receptors, Antigen, T-Cell. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 128 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Chimeric antigen receptor (CAR) T cells effectively treat B cell malignancies. However, CAR-T cells cause inflammatory toxicities such as cytokine release syndrome (CRS), which is in contrast to T cell receptor (TCR)–engineered T cells against various antigens that historically have rarely been associated with CRS. To study whether and how differences in receptor types affect the propensity for eliciting inflammatory responses in a model system wherein TCR and CAR target equalized sources of clinically relevant antigen, we discovered a CD22-specific TCR and compared it to CD22 CAR. Both CD22 TCR-T and CD22 CAR-T cells eradicated leukemia in xenografts, but only CD22 CAR-T cells induced dose-dependent systemic inflammation. Compared to TCR-T cells, CAR-T cells disproportionately upregulated inflammatory pathways without concordant augmentation in pathways involved in direct cytotoxicity upon antigen engagement. These differences in antileukemia responses comparing TCR-T and CAR-T cells highlight the potential opportunity to improve therapeutic safety by using TCRs.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Sialic Acid Binding Ig-like Lectin 2Receptors, Chimeric AntigenInflammationReceptors, Antigen, T-CellT-LymphocytesImmunotherapy, AdoptiveLeukemiaCytotoxicity, ImmunologicHumansAnimalsMiceCell Line, TumorXenograft Model Antitumor Assays

Substanzen

Sialic Acid Binding Ig-like Lectin 2Receptors, Chimeric AntigenReceptors, Antigen, T-CellCD22 protein, human

Autor:innen und Institutionen

  • Center for Immuno-Oncology, Center for Cancer Research (CCR), National Cancer Institute (NCI), National Institutes of Health (NIH), Bethesda, MD, USA.
  • Pediatric Oncology Branch, CCR, NCI, NIH, Bethesda, MD, USA.
  • Department of Safety Assessment, Genentech Inc., South San Francisco, CA, USA.
  • Single Cell Analysis Facility, CCR, NCI, NIH, Bethesda, MD, USA.
  • Laboratory of Integrative Cancer Immunology, CCR, NCI, NIH, Bethesda, MD, USA.
  • Cancer Research Technology Program, Frederick National Laboratory for Cancer Research, NCI, NIH, Frederick, MD, USA.

ORCID-Profile: Kilyna A Nguyen, Zhihui Liu, John S Davies, Lindsey M Draper, Scott M Norberg, Sooraj R Achar, Gregoire Altan-Bonnet, Xiaolin Wu, Thomas J Meyer, Michael C Kelly, Naomi Taylor, Christian S Hinrichs, Kazusa Ishii

Förderung

  • NIH HHS

Zitieren

APA

Nguyen, K. A., Liu, Z., Davies, J. S., McIntosh, C. P., Draper, L. M., Norberg, S. M., Rae, Z., Achar, S. R., Altan-Bonnet, G., Zhang, L., Wu, X., Meyer, T. J., Kelly, M. C., Taylor, N., Hinrichs, C. S., & Ishii, K. (2025). CD22 TCR-engineered T cells exert antileukemia cytotoxicity without causing inflammatory responses. Science Advances. https://doi.org/10.1126/sciadv.adq4297

Vancouver

Nguyen KA, Liu Z, Davies JS, McIntosh CP, Draper LM, Norberg SM, et al. CD22 TCR-engineered T cells exert antileukemia cytotoxicity without causing inflammatory responses. Science Advances. 2025. doi:10.1126/sciadv.adq4297

BibTeX
@article{Nguyen2025,
  author = {Nguyen, Kilyna A and Liu, Zhihui and Davies, John S and McIntosh, Crystal P and Draper, Lindsey M and Norberg, Scott M and Rae, Zachary and Achar, Sooraj R and Altan-Bonnet, Gregoire and Zhang, Ling and Wu, Xiaolin and Meyer, Thomas J and Kelly, Michael C and Taylor, Naomi and Hinrichs, Christian S and Ishii, Kazusa},
  title = {CD22 TCR-engineered T cells exert antileukemia cytotoxicity without causing inflammatory responses},
  journal = {Science Advances},
  year = {2025},
  doi = {10.1126/sciadv.adq4297}
}
Kostenlos starten →